FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1696992097> ?p ?o ?g. }

• W1696992097 endingPage "1397" @default.
• W1696992097 startingPage "1389" @default.
• W1696992097 abstract "Background Despite the success of rotavirus vaccines, suboptimal vaccine efficacy in regions with a high burden of disease continues to present a challenge to worldwide implementation. A birth dose strategy with a vaccine developed from an asymptomatic neonatal rotavirus strain has the potential to address this challenge and provide protection from severe rotavirus disease from birth. Methods This phase 2a randomised, double-blind, three-arm, placebo-controlled safety and immunogenicity trial was undertaken at a single centre in New Zealand between Jan 13, 2012, and April 17, 2014. Healthy, full-term (≥36 weeks gestation) babies, who weighed at least 2500 g, and were 0–5 days old at the time of randomisation were randomly assigned (1:1:1; computer-generated; telephone central allocation) according to a concealed block randomisation schedule to oral RV3-BB vaccine with the first dose given at 0–5 days after birth (neonatal schedule), to vaccine with the first dose given at about 8 weeks after birth (infant schedule), or to placebo. The primary endpoint was cumulative vaccine take (serum immune response or stool shedding of vaccine virus after any dose) after three doses. The immunogenicity analysis included all randomised participants with available outcome data. This trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12611001212943. Findings 95 eligible participants were randomised, of whom 89 were included in the primary analysis. A cumulative vaccine take was detected in 27 (90%) of 30 participants in the neonatal schedule group after three doses of RV3-BB vaccine compared with four (13%) of 32 participants in the placebo group (difference in proportions 0·78, 95% CI 0·55–0·88; p<0·0001). 25 (93%) of 27 participants in the infant schedule group had a cumulative vaccine take after three doses compared with eight (25%) of 32 participants in the placebo group (difference in proportions 0·68, 0·44–0·81; p<0·0001). A serum IgA response was detected in 19 (63%) of 30 participants and 20 (74%) of 27 participants, and stool shedding of RV3-BB was detected in 21 (70%) of 30 participants and 21 (78%) of 27 participants in the neonatal and infant schedule groups, respectively. The frequency of solicited and unsolicited adverse events was similar across the treatment groups. RV3-BB vaccine was not associated with an increased frequency of fever or gastrointestinal symptoms compared with placebo. Interpretation RV3-BB vaccine was immunogenic and well tolerated when given as a three-dose neonatal or infant schedule. A birth dose strategy of RV3-BB vaccine has the potential to improve the effectiveness and implementation of rotavirus vaccines. Funding Australian National Health and Medical Research Council, the New Zealand Health Research Council, and the Murdoch Childrens Research Institute. Despite the success of rotavirus vaccines, suboptimal vaccine efficacy in regions with a high burden of disease continues to present a challenge to worldwide implementation. A birth dose strategy with a vaccine developed from an asymptomatic neonatal rotavirus strain has the potential to address this challenge and provide protection from severe rotavirus disease from birth. This phase 2a randomised, double-blind, three-arm, placebo-controlled safety and immunogenicity trial was undertaken at a single centre in New Zealand between Jan 13, 2012, and April 17, 2014. Healthy, full-term (≥36 weeks gestation) babies, who weighed at least 2500 g, and were 0–5 days old at the time of randomisation were randomly assigned (1:1:1; computer-generated; telephone central allocation) according to a concealed block randomisation schedule to oral RV3-BB vaccine with the first dose given at 0–5 days after birth (neonatal schedule), to vaccine with the first dose given at about 8 weeks after birth (infant schedule), or to placebo. The primary endpoint was cumulative vaccine take (serum immune response or stool shedding of vaccine virus after any dose) after three doses. The immunogenicity analysis included all randomised participants with available outcome data. This trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12611001212943. 95 eligible participants were randomised, of whom 89 were included in the primary analysis. A cumulative vaccine take was detected in 27 (90%) of 30 participants in the neonatal schedule group after three doses of RV3-BB vaccine compared with four (13%) of 32 participants in the placebo group (difference in proportions 0·78, 95% CI 0·55–0·88; p<0·0001). 25 (93%) of 27 participants in the infant schedule group had a cumulative vaccine take after three doses compared with eight (25%) of 32 participants in the placebo group (difference in proportions 0·68, 0·44–0·81; p<0·0001). A serum IgA response was detected in 19 (63%) of 30 participants and 20 (74%) of 27 participants, and stool shedding of RV3-BB was detected in 21 (70%) of 30 participants and 21 (78%) of 27 participants in the neonatal and infant schedule groups, respectively. The frequency of solicited and unsolicited adverse events was similar across the treatment groups. RV3-BB vaccine was not associated with an increased frequency of fever or gastrointestinal symptoms compared with placebo. RV3-BB vaccine was immunogenic and well tolerated when given as a three-dose neonatal or infant schedule. A birth dose strategy of RV3-BB vaccine has the potential to improve the effectiveness and implementation of rotavirus vaccines." @default.
• W1696992097 created "2016-06-24" @default.
• W1696992097 creator A5000293904 @default.
• W1696992097 creator A5004429723 @default.
• W1696992097 creator A5007425462 @default.
• W1696992097 creator A5013467971 @default.
• W1696992097 creator A5014438210 @default.
• W1696992097 creator A5022445283 @default.
• W1696992097 creator A5030171291 @default.
• W1696992097 creator A5039335545 @default.
• W1696992097 creator A5040608645 @default.
• W1696992097 creator A5046147407 @default.
• W1696992097 creator A5049073933 @default.
• W1696992097 creator A5050094549 @default.
• W1696992097 creator A5053274176 @default.
• W1696992097 creator A5053499423 @default.
• W1696992097 creator A5056295664 @default.
• W1696992097 creator A5080331902 @default.
• W1696992097 date "2015-12-01" @default.
• W1696992097 modified "2023-09-27" @default.
• W1696992097 title "Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial" @default.
• W1696992097 cites W1667485201 @default.
• W1696992097 cites W1964845583 @default.
• W1696992097 cites W1985494124 @default.
• W1696992097 cites W1986185553 @default.
• W1696992097 cites W1987459358 @default.
• W1696992097 cites W1989645075 @default.
• W1696992097 cites W1992388983 @default.
• W1696992097 cites W1994632625 @default.
• W1696992097 cites W1999762730 @default.
• W1696992097 cites W2022086407 @default.
• W1696992097 cites W2025669883 @default.
• W1696992097 cites W2025908529 @default.
• W1696992097 cites W2049590113 @default.
• W1696992097 cites W2050300356 @default.
• W1696992097 cites W2052162631 @default.
• W1696992097 cites W2056468776 @default.
• W1696992097 cites W2064512224 @default.
• W1696992097 cites W2071848254 @default.
• W1696992097 cites W2077035982 @default.
• W1696992097 cites W2087156294 @default.
• W1696992097 cites W2089710044 @default.
• W1696992097 cites W2093046702 @default.
• W1696992097 cites W2096913021 @default.
• W1696992097 cites W2101380815 @default.
• W1696992097 cites W2113014022 @default.
• W1696992097 cites W2126953565 @default.
• W1696992097 cites W2127516971 @default.
• W1696992097 cites W2129511789 @default.
• W1696992097 cites W2138715674 @default.
• W1696992097 cites W2143233237 @default.
• W1696992097 cites W2154855506 @default.
• W1696992097 cites W2169605506 @default.
• W1696992097 cites W2170749337 @default.
• W1696992097 cites W2334047011 @default.
• W1696992097 cites W4231603137 @default.
• W1696992097 doi "https://doi.org/10.1016/s1473-3099(15)00227-3" @default.
• W1696992097 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26318715" @default.
• W1696992097 hasPublicationYear "2015" @default.
• W1696992097 type Work @default.
• W1696992097 sameAs 1696992097 @default.
• W1696992097 citedByCount "63" @default.
• W1696992097 countsByYear W16969920972015 @default.
• W1696992097 countsByYear W16969920972016 @default.
• W1696992097 countsByYear W16969920972017 @default.
• W1696992097 countsByYear W16969920972018 @default.
• W1696992097 countsByYear W16969920972019 @default.
• W1696992097 countsByYear W16969920972020 @default.
• W1696992097 countsByYear W16969920972021 @default.
• W1696992097 countsByYear W16969920972022 @default.
• W1696992097 countsByYear W16969920972023 @default.
• W1696992097 crossrefType "journal-article" @default.
• W1696992097 hasAuthorship W1696992097A5000293904 @default.
• W1696992097 hasAuthorship W1696992097A5004429723 @default.
• W1696992097 hasAuthorship W1696992097A5007425462 @default.
• W1696992097 hasAuthorship W1696992097A5013467971 @default.
• W1696992097 hasAuthorship W1696992097A5014438210 @default.
• W1696992097 hasAuthorship W1696992097A5022445283 @default.
• W1696992097 hasAuthorship W1696992097A5030171291 @default.
• W1696992097 hasAuthorship W1696992097A5039335545 @default.
• W1696992097 hasAuthorship W1696992097A5040608645 @default.
• W1696992097 hasAuthorship W1696992097A5046147407 @default.
• W1696992097 hasAuthorship W1696992097A5049073933 @default.
• W1696992097 hasAuthorship W1696992097A5050094549 @default.
• W1696992097 hasAuthorship W1696992097A5053274176 @default.
• W1696992097 hasAuthorship W1696992097A5053499423 @default.
• W1696992097 hasAuthorship W1696992097A5056295664 @default.
• W1696992097 hasAuthorship W1696992097A5080331902 @default.
• W1696992097 hasConcept C126322002 @default.
• W1696992097 hasConcept C142724271 @default.
• W1696992097 hasConcept C168563851 @default.
• W1696992097 hasConcept C187212893 @default.
• W1696992097 hasConcept C203014093 @default.
• W1696992097 hasConcept C203092338 @default.
• W1696992097 hasConcept C204787440 @default.
• W1696992097 hasConcept C22070199 @default.
• W1696992097 hasConcept C27081682 @default.
• W1696992097 hasConcept C2777227250 @default.

• next